ImmunityBio

ImmunityBio, Inc. is a clinical-stage biotechnology company based in Culver City, California. Founded by Dr. Patrick Soon-Shiong, the company focuses on developing innovative therapies and vaccines that enhance the immune system to combat cancer and infectious diseases. As a subsidiary of NantWorks LLC, ImmunityBio manages various stages of its product development and manufacturing processes. The company is actively engaged in several key research areas, including cancer immunotherapies for multiple myeloma and solid tumors, as well as COVID-19 vaccine development. Its clinical pipeline features products like Anktiva, which is in Phase 3 for bladder cancer, and other therapies targeting lymphopenia and pancreatic cancer. ImmunityBio also collaborates with other biotech firms, exemplified by its agreement with BeiGene, Ltd. for a Phase 3 trial in non-small cell lung cancer. With a dedicated team of approximately 680 employees, ImmunityBio is committed to advancing next-generation treatments tailored to individual patient needs.